 |
4-[(2E)-1-oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide |
|---|---|
| Trade Name | |
| Orphan Indication | Retinitis pigmentosa |
| EU Market Approval | EU |
| EU Designation Date | 2016-05-30 00:00:00 |
| Sponsor | Shire Pharmaceuticals Ireland Limited |
Related Access Program